[
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $798.89 as of July 23rd. LLY’s trailing and forward P/E were 65.00 and 36.63 respectively according to Yahoo Finance. Eli Lilly remains […]",
    "url": "https://finnhub.io/api/news?id=ddc0477f2b31c985e9db2d509c7217e37eb6e596180b932cea4395f6485d426c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753387472,
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "id": 136084780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $798.89 as of July 23rd. LLY’s trailing and forward P/E were 65.00 and 36.63 respectively according to Yahoo Finance. Eli Lilly remains […]",
      "url": "https://finnhub.io/api/news?id=ddc0477f2b31c985e9db2d509c7217e37eb6e596180b932cea4395f6485d426c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics",
    "summary": "Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that potentially strengthens its innovative pipeline. During the same period, the FDA approved a label update for the company's Alzheimer's treatment, Kisunla, optimizing its dosing schedule and potentially enhancing its market appeal. These developments coincided with a 3.67% rise in the company's share price over the past month. Although the market itself experienced an...",
    "url": "https://finnhub.io/api/news?id=7cf2e9ad7d2dc619ab4f77fd188f8e56d89197049fc2927d8f108dedfbb0962d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753378513,
      "headline": "Eli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics",
      "id": 136084781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that potentially strengthens its innovative pipeline. During the same period, the FDA approved a label update for the company's Alzheimer's treatment, Kisunla, optimizing its dosing schedule and potentially enhancing its market appeal. These developments coincided with a 3.67% rise in the company's share price over the past month. Although the market itself experienced an...",
      "url": "https://finnhub.io/api/news?id=7cf2e9ad7d2dc619ab4f77fd188f8e56d89197049fc2927d8f108dedfbb0962d"
    }
  },
  {
    "ts": null,
    "headline": "The 3 Things That Matter for Eli Lilly Now",
    "summary": "Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts.  The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.  The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects.",
    "url": "https://finnhub.io/api/news?id=82b5fa699ec1c6cd39981128d85d68d0a460b70c75145c1499c497db845b79cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366500,
      "headline": "The 3 Things That Matter for Eli Lilly Now",
      "id": 136066208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts.  The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.  The drugmaker's shares look expensive, but the premium is justified given Lilly's prospects.",
      "url": "https://finnhub.io/api/news?id=82b5fa699ec1c6cd39981128d85d68d0a460b70c75145c1499c497db845b79cb"
    }
  },
  {
    "ts": null,
    "headline": "This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.",
    "summary": "Viking Therapeutics  stock fell Thursday after it reported a widening quarterly earnings loss—but that doesn’t mean it won’t eventually pose a threat to  Eli Lilly  and  Novo Nordisk  in the weight-loss drug market.  While the company has several weight-loss drugs in different stages of development, a particularly important factor for the stock will be the clinica -trial results for its closely watched oral weight-loss drug, VK2735.  William Blair analyst Andy Hsieh expects the data to come in August.",
    "url": "https://finnhub.io/api/news?id=ab4bdb0ced10ccf05c0b11b4833d096f6d4c83716b9322a0c8ded90654878822",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753366200,
      "headline": "This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.",
      "id": 136066209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics  stock fell Thursday after it reported a widening quarterly earnings loss—but that doesn’t mean it won’t eventually pose a threat to  Eli Lilly  and  Novo Nordisk  in the weight-loss drug market.  While the company has several weight-loss drugs in different stages of development, a particularly important factor for the stock will be the clinica -trial results for its closely watched oral weight-loss drug, VK2735.  William Blair analyst Andy Hsieh expects the data to come in August.",
      "url": "https://finnhub.io/api/news?id=ab4bdb0ced10ccf05c0b11b4833d096f6d4c83716b9322a0c8ded90654878822"
    }
  },
  {
    "ts": null,
    "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
    "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
    "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365900,
      "headline": "How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?",
      "id": 136084782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.",
      "url": "https://finnhub.io/api/news?id=3b7ca2d9b2013ad37d57522728e29525f5e55b17922fe474c9a6de14a9684973"
    }
  },
  {
    "ts": null,
    "headline": "Lilly confirms date and conference call for second-quarter 2025 financial results announcement",
    "summary": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://finnhub.io/api/news?id=15a63dc32ecef17382b373ca61bc9a21c456ec0701d146c2c0969658444dc6b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753365600,
      "headline": "Lilly confirms date and conference call for second-quarter 2025 financial results announcement",
      "id": 136066210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
      "url": "https://finnhub.io/api/news?id=15a63dc32ecef17382b373ca61bc9a21c456ec0701d146c2c0969658444dc6b2"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc. ‘s share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in […]",
    "url": "https://finnhub.io/api/news?id=98dbbd5056713791a5bf82fa72d81d96d3e7cf37f6ec6653c8e84a703914f7a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753364904,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 136066211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc. ‘s share was trading at $32.07 as of July 17th. Viking Therapeutics (VKTX), a ~$3.45B biotech firm, is flying under the radar despite its potentially transformative role in […]",
      "url": "https://finnhub.io/api/news?id=98dbbd5056713791a5bf82fa72d81d96d3e7cf37f6ec6653c8e84a703914f7a7"
    }
  },
  {
    "ts": null,
    "headline": "Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche",
    "summary": "The Global Selective Estrogen Receptor Degrader (SERD) Market is rapidly evolving, highlighted by key innovations like FDA-approved Orserdu and the upcoming vepdegestrant, a pioneering PROTAC-based SERD by Pfizer and Arvinas. With over 25 fulvestrant generics available, the landscape is dynamic and expanding beyond breast cancer.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trial",
    "url": "https://finnhub.io/api/news?id=0783770553bbb78149b0d106719e58e309e6ce54870efd66245ffc2094763625",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753363740,
      "headline": "Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche",
      "id": 136066212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Global Selective Estrogen Receptor Degrader (SERD) Market is rapidly evolving, highlighted by key innovations like FDA-approved Orserdu and the upcoming vepdegestrant, a pioneering PROTAC-based SERD by Pfizer and Arvinas. With over 25 fulvestrant generics available, the landscape is dynamic and expanding beyond breast cancer.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The \"Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trial",
      "url": "https://finnhub.io/api/news?id=0783770553bbb78149b0d106719e58e309e6ce54870efd66245ffc2094763625"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Growth Company Fund Q2 2025 Commentary",
    "summary": "Fidelity Growth Company Fund beat its benchmark with smart AI bets like Nvidia and CoreWeave. See how itâs positioned for more. Explore the full review.",
    "url": "https://finnhub.io/api/news?id=5673cc286fe8ad1d7e8d33bae3e8a55fd552d86b240366db424591cbfd36df2d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753360500,
      "headline": "Fidelity Growth Company Fund Q2 2025 Commentary",
      "id": 136068440,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307631/image_1367307631.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Fidelity Growth Company Fund beat its benchmark with smart AI bets like Nvidia and CoreWeave. See how itâs positioned for more. Explore the full review.",
      "url": "https://finnhub.io/api/news?id=5673cc286fe8ad1d7e8d33bae3e8a55fd552d86b240366db424591cbfd36df2d"
    }
  },
  {
    "ts": null,
    "headline": "West Pharma soars on profit forecast raise, lowered tariff impact estimate",
    "summary": "(Reuters) -West Pharmaceutical raised its annual profit forecast and trimmed its estimates for tariff impact on Thursday, sending the medical equipment maker's shares up 24% in early trading.  West Pharma is deploying \"every available mitigation lever\" to offset the impact, but has not factored any potential tariffs related to future customer revenues into its current outlook, executives said in a call with analysts.  West Pharma's products are used by major pharmaceutical firms, including Eli Lilly and Novo Nordisk, in the administration of a wide range of therapies.",
    "url": "https://finnhub.io/api/news?id=173db8ce2f6f0876ade3ec1c5a224453e4ba5bdbf4c858319859163a221bb85c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358561,
      "headline": "West Pharma soars on profit forecast raise, lowered tariff impact estimate",
      "id": 136066213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -West Pharmaceutical raised its annual profit forecast and trimmed its estimates for tariff impact on Thursday, sending the medical equipment maker's shares up 24% in early trading.  West Pharma is deploying \"every available mitigation lever\" to offset the impact, but has not factored any potential tariffs related to future customer revenues into its current outlook, executives said in a call with analysts.  West Pharma's products are used by major pharmaceutical firms, including Eli Lilly and Novo Nordisk, in the administration of a wide range of therapies.",
      "url": "https://finnhub.io/api/news?id=173db8ce2f6f0876ade3ec1c5a224453e4ba5bdbf4c858319859163a221bb85c"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Contrafund Q2 2025 Commentary",
    "summary": "Fidelity Contrafund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=f41b1053b16d2cd041d9051d528960194cf1faaa7c3f62fe170a46de00d23734",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358400,
      "headline": "Fidelity Contrafund Q2 2025 Commentary",
      "id": 136068338,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f41b1053b16d2cd041d9051d528960194cf1faaa7c3f62fe170a46de00d23734"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Verve announce expiration of Verve tender offer",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares (\"Shares\") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net",
    "url": "https://finnhub.io/api/news?id=5f9ac388cb2aee4724f9f2dfca84818680a9a55d91e532cb76602f5ade457830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358400,
      "headline": "Lilly and Verve announce expiration of Verve tender offer",
      "id": 136066215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares (\"Shares\") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (\"CVR\") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net",
      "url": "https://finnhub.io/api/news?id=5f9ac388cb2aee4724f9f2dfca84818680a9a55d91e532cb76602f5ade457830"
    }
  },
  {
    "ts": null,
    "headline": "Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines",
    "summary": "BRISBANE, Calif., July 24, 2025--Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company (\"Lilly\") to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate’s molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-t",
    "url": "https://finnhub.io/api/news?id=6d041c5378d8643a82960fde41701175919e72354d201bc5f62ded9409823a50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753358400,
      "headline": "Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines",
      "id": 136066214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BRISBANE, Calif., July 24, 2025--Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company (\"Lilly\") to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate’s molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-t",
      "url": "https://finnhub.io/api/news?id=6d041c5378d8643a82960fde41701175919e72354d201bc5f62ded9409823a50"
    }
  },
  {
    "ts": null,
    "headline": "Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results",
    "summary": "Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results",
    "url": "https://finnhub.io/api/news?id=eaf5a957b4f4d5d7ee2384fd74266fa34314dbe14a9d10fc5bfc865b200a118d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753356980,
      "headline": "Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results",
      "id": 136068104,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eaf5a957b4f4d5d7ee2384fd74266fa34314dbe14a9d10fc5bfc865b200a118d"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Blue Chip Growth Fund Q2 2025 Commentary",
    "summary": "For the quarter, the fund's Retail Class shares gained 19.83%, outpacing the 17.84% advance of the benchmark, the Russell 1000Â® Growth Index.",
    "url": "https://finnhub.io/api/news?id=22ca2da0f1f333888586a2ec3dcb39d3243d6f581dc8186974f81f819586396c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753351140,
      "headline": "Fidelity Blue Chip Growth Fund Q2 2025 Commentary",
      "id": 136065892,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039336845/image_2039336845.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For the quarter, the fund's Retail Class shares gained 19.83%, outpacing the 17.84% advance of the benchmark, the Russell 1000Â® Growth Index.",
      "url": "https://finnhub.io/api/news?id=22ca2da0f1f333888586a2ec3dcb39d3243d6f581dc8186974f81f819586396c"
    }
  },
  {
    "ts": null,
    "headline": "Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care",
    "summary": "Explore the evolving landscape of the Global Benign Breast Disease and Early Breast Cancer market from 2025-2035. Benign Breast Disease encompasses non-cancerous conditions like fibrocystic changes, manageable through non-invasive treatments. Meanwhile, Early Breast Cancer, detected in stages 0-2, benefits from advanced therapies and early intervention. Rising awareness and innovations in screening, such as 3D mammography, are propelling market growth. However, high costs of treatments and unequ",
    "url": "https://finnhub.io/api/news?id=5f4e027a5d9c175e2fc80f07e4a8b2a06778fba13bbbfcce64d8d5544219657d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753350360,
      "headline": "Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care",
      "id": 136066216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Explore the evolving landscape of the Global Benign Breast Disease and Early Breast Cancer market from 2025-2035. Benign Breast Disease encompasses non-cancerous conditions like fibrocystic changes, manageable through non-invasive treatments. Meanwhile, Early Breast Cancer, detected in stages 0-2, benefits from advanced therapies and early intervention. Rising awareness and innovations in screening, such as 3D mammography, are propelling market growth. However, high costs of treatments and unequ",
      "url": "https://finnhub.io/api/news?id=5f4e027a5d9c175e2fc80f07e4a8b2a06778fba13bbbfcce64d8d5544219657d"
    }
  }
]